These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 15673692)
21. Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol. Richette P; Bardin T Nat Clin Pract Rheumatol; 2006 Jun; 2(6):338-42; quiz 343. PubMed ID: 16932713 [TBL] [Abstract][Full Text] [Related]
22. Therapeutic perspectives on uricases for gout. Garay RP; El-Gewely MR; Labaune JP; Richette P Joint Bone Spine; 2012 May; 79(3):237-42. PubMed ID: 22366146 [TBL] [Abstract][Full Text] [Related]
25. New treatments for gout. Perez-Ruiz F Joint Bone Spine; 2007 Jul; 74(4):313-5. PubMed ID: 17606397 [No Abstract] [Full Text] [Related]
26. Diagnosis and treatment of gout. Meltzler M BMJ Case Rep; 2014 Feb; 2014():. PubMed ID: 24493155 [No Abstract] [Full Text] [Related]
27. Pegloticase failure and a possible solution: Immunosuppression to prevent intolerance and inefficacy in patients with gout. Berhanu AA; Krasnokutsky S; Keenan RT; Pillinger MH Semin Arthritis Rheum; 2017 Jun; 46(6):754-758. PubMed ID: 27769591 [TBL] [Abstract][Full Text] [Related]
28. Recapture and improved outcome of pegloticase response with methotrexate-A report of two cases and review of the literature. Bessen SY; Bessen MY; Yung CM Semin Arthritis Rheum; 2019 Aug; 49(1):56-61. PubMed ID: 30583886 [TBL] [Abstract][Full Text] [Related]
29. Rasburicase in the treatment of hyperuricemia of newborns. Ghirardello S; Ardissino G; Mastrangelo A; Mosca F Pediatr Nephrol; 2010 Sep; 25(9):1775; author reply 1777. PubMed ID: 20376501 [No Abstract] [Full Text] [Related]
30. Rasburicase for hyperuricemia in an extremely low birth weight infant. Canpolat FE; Cekmez F Indian Pediatr; 2011 Jul; 48(7):573-4. PubMed ID: 21813935 [No Abstract] [Full Text] [Related]
33. Effectiveness of a single fixed dose of rasburicase 3 mg in the management of tumour lysis syndrome. Coutsouvelis J; Wiseman M; Hui L; Poole S; Dooley M; Patil S; Avery S; Wei A; Spencer A Br J Clin Pharmacol; 2013 Feb; 75(2):550-3. PubMed ID: 22686734 [No Abstract] [Full Text] [Related]
34. Rasburicase and tumor lysis syndrome: lower dosage, consideration of indications, and hyperhydration. Darmon M; Guichard I; Vincent F J Clin Oncol; 2011 Jan; 29(3):e67-8; author reply e69. PubMed ID: 21149649 [No Abstract] [Full Text] [Related]
35. Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases. Rozenberg S; Roche B; Dorent R; Koeger AC; Borget C; Wrona N; Bourgeois P Rev Rhum Engl Ed; 1995 May; 62(5):392-4. PubMed ID: 7655872 [TBL] [Abstract][Full Text] [Related]
36. A costly therapeutic dilemma in tophaceous gout: is etanercept or rasburicase preferable? Reinders MK; van Roon EN; Brouwers JR; Jansen TL Ann Rheum Dis; 2005 Mar; 64(3):516; author reply 516. PubMed ID: 15708917 [No Abstract] [Full Text] [Related]
37. [Gout: an overview of available urate lowering therapies]. Richette P Ann Pharm Fr; 2012 May; 70(3):133-8. PubMed ID: 22655581 [TBL] [Abstract][Full Text] [Related]
38. Gout: a comprehensive review. Rymal E; Rizzolo D JAAPA; 2014 Sep; 27(9):26-31. PubMed ID: 25102078 [TBL] [Abstract][Full Text] [Related]
39. Rasburicase in the prevention and treatment of tumour lysis syndrome. Mayne N; Keady S; Thacker M Intensive Crit Care Nurs; 2008 Feb; 24(1):59-62. PubMed ID: 17698360 [TBL] [Abstract][Full Text] [Related]